CenterBook Partners LP Takes Position in Viridian Therapeutics, Inc. $VRDN

CenterBook Partners LP bought a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 136,717 shares of the company’s stock, valued at approximately $4,255,000.

Several other large investors also recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Viridian Therapeutics by 29.6% during the fourth quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock valued at $174,650,000 after acquiring an additional 1,280,161 shares in the last quarter. Commodore Capital LP lifted its position in shares of Viridian Therapeutics by 35.4% during the second quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock worth $68,152,000 after purchasing an additional 1,275,000 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Viridian Therapeutics by 12.8% during the fourth quarter. Geode Capital Management LLC now owns 1,992,174 shares of the company’s stock worth $62,007,000 after purchasing an additional 225,987 shares during the last quarter. Fisher Asset Management LLC lifted its position in shares of Viridian Therapeutics by 48.2% during the fourth quarter. Fisher Asset Management LLC now owns 1,780,284 shares of the company’s stock worth $55,402,000 after purchasing an additional 579,058 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Viridian Therapeutics by 65.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,264,047 shares of the company’s stock worth $39,337,000 after purchasing an additional 499,485 shares during the last quarter.

Viridian Therapeutics Stock Performance

Shares of NASDAQ VRDN opened at $15.73 on Tuesday. The company has a quick ratio of 15.15, a current ratio of 15.15 and a debt-to-equity ratio of 0.10. The firm’s 50-day moving average price is $16.36 and its two-hundred day moving average price is $25.64. Viridian Therapeutics, Inc. has a 52-week low of $13.18 and a 52-week high of $34.29. The stock has a market capitalization of $1.62 billion, a P/E ratio of -4.74 and a beta of 0.90.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Tuesday, May 5th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.16. Viridian Therapeutics had a negative net margin of 490.31% and a negative return on equity of 80.19%. The firm had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $0.04 million. During the same quarter last year, the company posted ($0.87) earnings per share. Viridian Therapeutics’s revenue was up 95.8% on a year-over-year basis. As a group, sell-side analysts forecast that Viridian Therapeutics, Inc. will post -3.87 earnings per share for the current year.

Insider Transactions at Viridian Therapeutics

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc bought 1,176,470 shares of the business’s stock in a transaction on Monday, May 11th. The shares were purchased at an average price of $17.00 per share, with a total value of $19,999,990.00. Following the completion of the acquisition, the director directly owned 5,090,928 shares of the company’s stock, valued at approximately $86,545,776. The trade was a 30.05% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 2.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on VRDN shares. The Goldman Sachs Group reduced their price target on shares of Viridian Therapeutics from $36.00 to $31.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viridian Therapeutics in a research report on Monday, April 20th. Stifel Nicolaus set a $39.00 price target on shares of Viridian Therapeutics in a research report on Wednesday, May 13th. Truist Financial reduced their price target on shares of Viridian Therapeutics from $36.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, April 21st. Finally, Wells Fargo & Company reduced their price target on shares of Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating on the stock in a research report on Tuesday, March 31st. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $36.14.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.